GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » Capex-to-Operating-Income

Rhinomed (ASX:RNO) Capex-to-Operating-Income : 0.00 (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Rhinomed Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Rhinomed's Capital Expenditure for the six months ended in Jun. 2023 was A$-0.06 Mil. Its Operating Income for the six months ended in Jun. 2023 was A$-3.95 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Rhinomed Capex-to-Operating-Income Historical Data

The historical data trend for Rhinomed's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhinomed Capex-to-Operating-Income Chart

Rhinomed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rhinomed Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rhinomed's Capex-to-Operating-Income

For the Medical Devices subindustry, Rhinomed's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhinomed's Capex-to-Operating-Income Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rhinomed's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Rhinomed's Capex-to-Operating-Income falls into.



Rhinomed Capex-to-Operating-Income Calculation

Rhinomed's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.095) / -9.094
=N/A

Rhinomed's Capex-to-Operating-Income for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.056) / -3.95
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhinomed  (ASX:RNO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Rhinomed Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Rhinomed's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhinomed (ASX:RNO) Business Description

Traded in Other Exchanges
Address
132 Gwynne Street, Level 1, Cremorne, VIC, AUS, 3121
Rhinomed Ltd is a medical technology company, with a patented nasal technology platform. It is engaged in the research, development and commercialization of consumer and medical devices including nasal, respiratory and nasal drug delivery technologies. It operates in one segment which is the identification, acquisition, and commercialization of late-stage consumer therapeutic and medical delivery technologies. The products of the company involve Rhinoswab, Mute, Turbine and Rhinoswab Junior. It operates geographically within North, Central, and South America, Asia-Pacific, Europe, Middle East, and Africa. The company earns majority of its revenue from Asia-Pacific.

Rhinomed (ASX:RNO) Headlines

No Headlines